#257 ‒ Cognitive decline, neurodegeneration, and head injuries: mitigation and prevention strategies, supplements, and more | Tommy Wood, M.D., Ph.D.
“If you’re trying to maintain a basic set of cognitive functions, [it is important] to actively work on ways to increase headroom, increase absolute capacity throughout the lifespan. Because at some point capacity will decrease, but you want to push that out as far as you can.” —Tommy Wood
#147 – Hussein Yassine, M.D.: Deep dive into the “Alzheimer’s gene” (APOE), brain health, and omega-3s
“What’s important is in science, you always have to be skeptical and you always need to find whether any particular study can be replicated or not before you make strong recommendations and adopt any drastic change and how you are consuming certain things, whether it’s a medication or a diet or a supplement.” — Hussein Yassine, M.D.
#134 – James O’Keefe, M.D.: Preventing cardiovascular disease and the risk of too much exercise
“If exercise were a drug, it would be the best drug we have for preventing heart disease . . .. But like with any drug, you’ve got to get the dose right.” — James O’Keefe
#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology
“Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring
#83 – Bill Harris, Ph.D.: Omega-3 fatty acids
“I don’t think [omega-6] is the evil that people think it is. The problem is that we need to get more EPA and DHA in our diet, not necessarily get all hung up on omega-6.” — Bill Harris
#24 – Tom Dayspring, M.D., FACP, FNLA – Part V of V: Lp(a), inflammation, oxLDL, remnants, and more
“Use the correct terminology with everything.” –Tom Dayspring
#23 – Tom Dayspring, M.D., FACP, FNLA – Part IV of V: statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain
“This is what it ultimately comes down to – and it’s the way you practice – you’ve got to individualize everything.” –Tom Dayspring